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After many years of open discussion and development [1–8],
the first genetically modified (GM) insect strains are entering field
trials [9,10]. A key engineered trait renders the insects
‘‘genetically sterile’’, such that some or all of their offspring die
[11–14]; the insects additionally carry a fluorescent marker gene
for easy identification. Such ‘‘genetic sterility’’ transgenes (in
genetic terms, conditional dominant lethal genes) are not able to
establish or spread in the wild due to their high fitness cost; such
self-limiting strategies are widely viewed as the lowest risk
category (e.g., [15]). Other genetic strategies are in development,
including more invasive genetic systems. Some of these, such as
those based on artificial infection with Wolbachia [16], may not be
covered by regulations narrowly focused on the use of
recombinant DNA technology despite having many similar
properties [17].
In their provocative opinion piece, Reeves et al. question aspects
of the regulatory process for GM insects [18]. Approval for limited
field releases of GM insects has been given in four countries at the
time of writing, and Reeves et al. consider aspects of three of these.
Their exclusive focus on GM insects allows room for some
interesting speculation about some potential features of an
idealised regulatory system. Conversely, ignoring established
regulatory systems and experience in other areas such insecticides,
drugs, vaccines, and GM crops unfortunately leads them to make
unworkable recommendations in several areas.
Regulatory agencies seek to permit the development of
beneficial new technology while minimising any potential harms.
Regulatory systems therefore need to identify and characterise
potential harms, and determine whether these should be accepted,
mitigated, or avoided. The degree of uncertainty in any a priori
analysis, especially where new technologies are concerned, leads to
an element of judgement, as does the identification and weight
attached to various protection goals. In some cases, potential
benefits may be taken into account and weighed against potential
risk. One indirect approach to this is to compare proposed actions
with the ‘‘no action’’ alternative or status quo. For insect control,
this is the current use of chemical insecticides plus uncontrolled
damage from the insect, e.g., for the dengue mosquito Aedes aegypti
50–100 million cases of dengue per year.
Reeves et al. correctly note the need for a science-based, case-
by-case assessment. For example, the ecological impact of
suppressing an invasive insect pest may be very different in its
region of origin relative to an area where it is has recently
established. However, the authors then criticise the United States
government’s regulation of GM insects on the ground that one
component, an environmental impact statement (EIS) [19], was
not sufficiently case-specific. This criticism is misplaced. As Reeves
et al. note elsewhere, ‘‘EIS documents can have a very broad
scope, as they are principally intended to evaluate the impact of
proposed agency policy changes on a broad programmatic basis at
a national level. EA [Environmental Assessment] documents
instead are generally focused on specific actions in a single species
at named locations’’. The US Department of Agriculture (USDA)
is to be commended on developing an EIS under the National
Environmental Protection Act to assess potential future program-
matic use of GM insects to augment its existing sterile-insect
control programmes. In addition, specific proposed activities with
engineered pink bollworm (Pectinophora gossypiella, a pest of cotton)
were given case-by-case assessment under the Plant Protection
Act. Remarkably, despite the longer history, rapid adoption, and
large-scale use of GM crops, this was the first EIS completed for
any genetically modified organism. This highlights the proactive
stance taken by US regulatory agencies with respect to GM
insects, as both developers and sceptics such as Reeves et al. would
doubtless wish.
Reeves et al. call for more transparency in the process, arguing
that it would instill greater public confidence if the regulators were
to ‘‘show their working’’ by publishing all permit applications,
associated data and reasoning, and detailed justification of their
conclusions. This argument has some merit, but needs to be
balanced against significant practical difficulties. Technology
developers have legitimate rights to protect proprietary informa-
tion; governments understand this and provide statutory protec-
tions. Reeves et al. criticise these protections without any
recognition of the reasons for their existence. Fortunately, this is
not an issue new to genetically modified organisms, and one can
look elsewhere for a balanced discussion, for example Walport and
Brest [20]. These authors are from philanthropic agencies funding
the research and strongly preferring full publication, yet still
recognise the ensuing trade-offs and pitfalls; developers might look
for stronger protection.
Reeves et al. confuse the concepts of transparency, indepen-
dence, and scientific quality. Regulators make robust, science-
based decisions, taking data and input from a wide range of
sources and using internal and external multi-disciplinary experts
to carefully assess data quality and gaps and potential harms and
mitigations, and ultimately determine a course of action that
appropriately protects all stakeholders. It is highly desirable that
regulators operate and communicate their decisions and the
background to them as fully as possible, but this is a separate issue
from the scientific quality of the decisions themselves. Regulators
are of course independent of the applicants, but it is nonsense to
suggest that the data inputs themselves should be independent.
Inevitably, the applicants will know more about the proposed
action and specifics of their technology and strains than anyone
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applicants, while recognising that applicants may have legitimate
needs for confidentiality. This requirement for full information to
ensure rigorous quality is therefore somewhat at odds with the
separate desire for transparency. Regulators are well used to
handling this tension, and do so in accordance with their national
culture and legislative framework. None of this is unique to GM
insects, arising similarly in the regulation of drugs, vaccines, and
even non-technology issues such as construction.
Reeves et al. are also on weak ground when they assert that
regulators should consider only information published in peer-
reviewed journals. This assertion depends on three assumptions: that
journal peer-review is a superior guarantee of quality than any other
method, that no data from any other source can be of adequate
quality to warrant consideration, and that regulators themselves are
incapable of adequately assessing the quality and significance of data
provided to them. Each of these assumptions is naı ¨ve at best.
Experienced researchers know that journal peer-review is an
imperfect process, a trade-off between economy of effort and
rigour, and is highly variable. An editor and two or so reviewers
with some relevant experience will review the paper, typically
focusing on their own area of expertise. For comparison, the
USDA’s EIS had a public scoping period to incorporate the widest
possible range of potential concerns from the outset, and a public
comment period to solicit comments on the draft. Unlike journal
peer-review, where competitors and others likely to have negative
views are routinely excluded, the draft EIS was specifically sent to
multiple GM-sceptic non-governmental organisations and indi-
viduals to solicit their comments, as well as to independent
scientific experts and others; in total, over 50 individuals.
Furthermore, the availability of the draft EIS was advertised on
the Federal Register and public meetings held in Washington,
D.C., and four representative states to allow yet more opportunity
for comment; these public meetings included presentations by
USDA scientists on the technology and the implications of its use.
Journals do not do this for papers, not because it is an inferior
process, quite the opposite, but simply because so comprehensive a
system would be unmanageable and unaffordable.
Furthermore, journals select papers for publication using criteria
that are not fully congruent with the needs of regulators. In
particular, it is difficult to publish negative data. Studies showing
lack of difference between a transgenic strain and its unmodified
wild-type counterpart may be of great interest to regulators but not
to journal editors. It took years to publish the USDA-Oxitec field
trials of an engineered strain of pink bollworm, in part because
editors at several journals felt that since the GM strain performed as
predicted from prior lab studies, and showed no strange behaviour
relative to a non-GM comparator strain, the paper was not
sufficiently exciting for their journal. PLoS ONE, unusually, looks for
quality irrespective of ‘‘novelty’’ and published the paper [9].
Reeves et al. display a striking distrust of the regulatory process,
and indeed of regulators themselves, which distorts their analysis.
The ultimate responsibility for decision-making in this area lies with
sovereign states. All of the countries discussed by Reeves et al. have
national legislation for environmental protection, animal welfare,
disease mitigation and control, etc., which covers the field use of
GM insects irrespective of whether the country has chosen to
regulate by technology process. Such legislation will take into
account obligations from international agreements to which they
are party (e.g., Cartagena, North American Plant Protection
Organization [NAPPO]). Indeed, a narrow focus on recombinant
DNA technology has led to regulatory gaps in dealing with other
genetic technologies such as Wolbachia, cis-genics, and in vivo site-
directed mutagenesis. Independent regulatory agencies, established
under national legislation, reviewthe proposaland data providedby
applicants.Suchagencieshave broadscientificexpertise,whichthey
supplement as needed by consulting external experts. This provides
the broad and deep independent scientific review advocated by
Reeves et al., though by a different mechanism. Both scoping and
review can engage a large number of experts across a wide range of
disciplines, as illustrated above for the US EIS. Reeves et al. rightly
commend the Malaysian regulators for their extraordinary efforts to
solicit comment both before and after approving a limited field
release of a GM mosquito.
Though the checklist provided by Reeves et al. is completely
inappropriate for its proposed purpose, assessing scientific quality,
the general concept of checklists within the regulatory process is a
good one. One step in the process is to identify the widest possible
range of potential harms, which can then be assessed for likelihood
and consequence in respect of the specific proposed action.
Checklists can help with this, though inevitably many items on a
comprehensive checklist of potential harms will not apply to a
specific proposal. This approach informed the development of
NAPPO standard RSPM 27 concerning transgenic arthropods,
and has been adopted in one form or another by several
subsequent initiatives. This may also help promote a harmonised
approach that would inform decision-making and aid transparen-
cy across multiple nations and agencies. External comment at this
scoping stage can also be very helpful, and was used by the US and
Malaysian regulatory authorities, for example.
Attention often focuses on the scientific and technical aspects of
new technology, rather than regulatory processes, so in that
respect the Viewpoint from Reeves et al. is welcome. However,
their specific prescriptions would harm, rather than help, these
processes. Fortunately, regulators have a much broader perspec-
tive and experience than Reeves et al. provide, and have proven
well able to meet the challenge of regulating GM insects, at least
for the relatively simple, minimal-risk systems so far developed.
Regulations and regulatory processes need to be consistent and
proportionate. This means that different genetic technologies
should be subject to similar scrutiny and assessment irrespective of
their methodological details—in other words, treated consistently.
Regulatory requirements should also be proportionate to potential
harm—as Reeves et al. note, the present GM insects are all in the
lowest-risk ‘‘sterile-insect’’ category. Consistent and proportionate
regulatory systems recognise this, and also that other genetic
technologies designed to persist in the environment may present
very different risk categories. So far, the agencies tasked to regulate
GM insects have appropriately taken a cautious, thorough
approach that allows progress towards realisation of the substantial
benefits GM insect technology could potentially provide, while
rigorously protecting the public and environment.
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